23.68
Elanco Animal Health Inc stock is traded at $23.68, with a volume of 3.63M.
It is up +2.38% in the last 24 hours and down -5.96% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$23.13
Open:
$23.51
24h Volume:
3.63M
Relative Volume:
0.72
Market Cap:
$11.83B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-50.78
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
+2.38%
1M Performance:
-5.96%
6M Performance:
+10.55%
1Y Performance:
+180.57%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Inc
|
23.68 | 11.83B | 4.72B | -232.00M | 284.00M | -0.4663 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health (NYSE:ELAN) Downgraded by Wall Street Zen to Buy - MarketBeat
174,412 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Elanco Animal Health Price Target Announced at $30.00/Share by Citigroup - Moomoo
Citi Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Elanco will detail first-quarter results in a May 6 webcast - Stock Titan
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 3.6% -- GF Value Says Still Overvalued - GuruFocus
ELAN Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
Citi Initiates Elanco Animal Health(ELAN.US) With Buy Rating, Announces Target Price $30 - Moomoo
Is Elanco (ELAN) Using Mass-Market Collars to Quietly Redefine Its Companion Animal Strategy? - Yahoo Finance
Is It Too Late To Consider Elanco Animal Health (ELAN) After Its 1-Year Share Price Surge? - Yahoo Finance
Animal Health Market Intelligence Report 2026-2034 Featuring Strategic Analysis of Bayer, Elanco, Merck, Merial, Zoetis, Boehringer Ingelheim, Ceva Sante Animale, Heska and More - Yahoo Finance
Citigroup Begins Coverage on Elanco Animal Health (NYSE:ELAN) - MarketBeat
Elanco Animal Health: Leading With Innovation, Impact, and Purpose - marketscreener.com
Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Up 49.0% in March - MarketBeat
630,840 Shares in Elanco Animal Health Incorporated $ELAN Acquired by Hardman Johnston Global Advisors LLC - MarketBeat
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Institution Moves: Is Elanco Animal Health Incorporated gaining market shareEarnings Performance Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Where is Elanco Animal Health Incorporated (ELAN) headed according to the Street? - MSN
DDD Partners LLC Decreases Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Elanco Animal Health Inc (STU:5EA) Bonds - GuruFocus
Elanco Animal Health Incorporat (ELAN) Stock forecasts - Yahoo Finance UK
Dimensional Fund Advisors (NYSE: ELAN) reports 24.5M shares beneficially owned - Stock Titan
Elanco Launches Advantage Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* - Finviz
Elanco Animal Health Inc (ELAN) Shares Gap Down to $22.82 on Apr 9 - GuruFocus
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* - PR Newswire
Elanco's new dog flea collar offers 4 months of coverage for under $25 - Stock Titan
Aug Sectors: Can Elanco Animal Health Incorporated expand its profit marginsLayoff News & Weekly Market Pulse Alerts - baoquankhu1.vn
Form DEF 14A Elanco Animal Health For: Dec 31 - StreetInsider
[DEF 14A] Elanco Animal Health Inc Definitive Proxy Statement - Stock Titan
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Elanco (ELAN) executive awarded new deferred stock units under deferral plan - Stock Titan
Elanco (NYSE: ELAN) CEO awarded new deferred stock units as compensation - Stock Titan
Elanco (ELAN) CFO awarded new deferred stock units in Form 4 filing - Stock Titan
Elanco (ELAN) officer granted 40,985 shares, with 20,288 withheld for taxes - Stock Titan
Stifel reiterates buy on Elanco stock, keeps $32 price target - Investing.com
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
IVF In Animals Market Generated Opportunities, Future Scope - openPR.com
Veterinary Medication Market Set for Dynamic Boom as Key Players - openPR.com
Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
ELAN Technical Analysis & Stock Price Forecast - intellectia.ai
ELAN PE Ratio & Valuation, Is ELAN Overvalued - Intellectia AI
Maryland judge dismisses securities class action against Elanco over Zenrelia disclosures - DVM360
Elanco (ELAN) director defers fees into 600 Deferred Stock Units - Stock Titan
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing Elanco Animal Health’s Valuation After Recent Share Price Swings And Product Launch Momentum - Yahoo Finance
Chewy reaches settlement in Elanco flea and tick antitrust litigation - DVM360
Elanco supports incubaFORUM ASIA 2026 as Premium-Platinum Sponsor - avinews.com
Decoquinate Market Is Going to Boom Rapidly With Top Key Players - openPR.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elanco Animal Health Inc Stock (ELAN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Modi Rajeev A. | SEE REMARKS |
Dec 11 '25 |
Buy |
21.33 |
4,500 |
95,985 |
123,082 |
| VanHimbergen Robert M | EVP and CFO |
Dec 11 '25 |
Buy |
21.64 |
6,950 |
150,426 |
124,233 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Dec 11 '25 |
Buy |
21.75 |
22,000 |
478,496 |
167,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):